Business Update

Biopharma company updates European commercialization strategy to reduce expenses

Published in Hepatitis Weekly, January 16th, 2006

Nabi Biopharmaceuticals (NABI) announced changes to its European commercialization strategy as it conducts an assessment of confirmatory phase III clinical trial results for StaphVAX (Staphylococcus aureus polysaccharide conjugate vaccine) and in an effort to reduce expenses.

In line with the company's decision to withdraw its marketing authorization application (MAA) in Europe, it has also closed its operations in Europe. Nabi Biopharmaceuticals remains committed to advancing the commercialization of PhosLo (calcium acetate) and Hebig in Europe and, upon their approval, the company's focus will be on the launch of these two critical therapies through a sales...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2006-01-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry